Proteomics News and Research

RSS

The term 'proteome' was first coined in 1994, and refers to all the proteins in a cell, tissue, or organism. Proteomics refers to the study of the proteome. Because proteins are involved in almost all biological activities, the proteome is a rich source of biological information.

Antidepressants and mood stabilizers may benefit stroke victims

A study in rodents shows the growth of new neurons, also known as neurogenesis, lessens the severity of stroke and dramatically improves function following a stroke. The research, undertaken at the Buck Institute for Age Research, suggests that drugs shown to promote neurogenesis in rodents could have benefits for human stroke victims and that those drugs-which include antidepressants and mood stabilizers such as lithium-may be suitable for study in human clinical trials.

13 Apr 2010

AB SCIEX announces formal opening of Asia Pacific Application Support Center in Shanghai

AB SCIEX, a global leader in life science analytical technologies, today announced the formal opening of its Asia Pacific Application Support Center in Shanghai. With state-of-the-art, award-winning facilities, the new Application Support Center serves as a regional center of excellence for comprehensive service, support and application development to enable the science community in China and the region to continue its increasing use of mass spectrometry and complementary technologies for a broad range of applications.

12 Apr 2010

Illumina launches VeraCode ADME Core Panel

Illumina, Inc. today announced the launch of its VeraCode ADME Core Panel designed to help researchers study genetic predispositions for differential drug response and adverse events. The VeraCode ADME Core Panel offers the most complete representation of the key biomarkers associated with drug absorption, distribution, metabolism and excretion (ADME) as standardized by pharmaceutical industry experts in the PharmADME Core List.

From Illumina, Inc. 7 Apr 2010

Study: 75% of men with diabetes will develop some degree of ED

Erectile dysfunction is one of the most prevalent diabetes-induced complications in men; current estimates suggest that as many as 75% of men with diabetes will develop some degree of ED, and in many cases diabetics develop more severe forms of ED that are less responsive to standard drugs.

7 Apr 2010

AnaptysBio, VLST collaborate to generate novel multi-antigen specific antibody therapeutics

AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced a collaboration with VLST Corporation to generate novel multi-antigen specific antibody therapeutics for the treatment of autoimmune and inflammatory disorders. This is the fourth collaboration announced by AnaptysBio during 2010.

5 Apr 2010

Winner of 2010-2011 Luminex/ACMGF Award

The American College of Medical Genetics Foundation (ACMGF) has awarded Dr. Marilyn M. Li, of the Tulane Medical Center and the Tulane University School of Medicine the 2010-2011 Luminex/ACMGF Award at the ACMG 2010 Annual Clinical Genetics Meeting in Albuquerque, NM.

From Luminex 3 Apr 2010

New Prestige Antibodies powered by Atlas Antibodies added to Sigma Life Science's portfolio

Sigma® Life Science, the innovative biological products and services brand of Sigma-Aldrich®, today announced that it has added 2,200 new Prestige Antibodies® powered by Atlas Antibodies to its industry-leading portfolio.

From Atlas Antibodies 29 Mar 2010

CTSI licenses GeneGo's pathway analysis suite and database searching tool

GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that the Indiana Clinical and Translational Sciences Institute has licensed its pathway analysis suite MetaCore and its database searching tool Eureka.

23 Mar 2010

Pressure BioSciences announces presentations on advantages of PCT

Pressure BioSciences, Inc. today announced that five presentations on the advantages of pressure cycling technology (PCT) in the preparation, processing, identification, and quantification of proteins were made at last week's annual meeting of US HUPO (Human Proteomics Organization) in Denver, Colorado.

From Thermo Fisher Scientific Inc. 19 Mar 2010

ALS TDI, Aestus Therapeutics to test potential small-molecule compounds to stop progression of ALS

The ALS Therapy Development Institute and Aestus Therapeutics, Inc., announced their plans today to test several potential small-molecule compounds to slow or stop the progression of Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's disease).

17 Mar 2010

Kinexus Bioinformatics launches new peptide synthesis facility

Kinexus Bioinformatics Corporation, a world leader in functional proteomics research, announced the launch of a new peptide synthesis facility to provide researchers with the latest in peptide array technologies. These new services will facilitate and expedite access to peptide platforms for innovative approaches to proteomic research and discovery.

16 Mar 2010

Illumina announces enhancement to OmniExpress BeadChip

Illumina, Inc. today unveiled its new HumanOmniExpress+ Custom BeadChip (OmniExpress+), an enhancement to the recently announced OmniExpress BeadChip that allows for the addition of up to 200,000 custom variants for a total of >900k variants per sample. OmniExpress+ leverages the proven iSelect custom genotyping infrastructure to provide researchers with unlimited flexibility in adding custom content for disease or pathway-specific markers, rare variants from the 1,000 Genomes Project, or panels for fine-mapping onto the industry’s most optimal set of SNPs.

From Illumina, Inc. 16 Mar 2010

International symposium to feature latest findings on vector-borne diseases in humans and plants

Leading insect vector biologists from around the world will gather at the University of California, Riverside for two days this month to discuss their latest research on vector-borne diseases in humans and plants.

16 Mar 2010

UVA, Merck collaborate to discover novel drugs for women's reproductive health

The University of Virginia in Charlottesville today announced that it has entered into a research collaboration with Merck (known as MSD outside the United States and Canada) to discover novel drugs for women's reproductive health.

12 Mar 2010

TGen, Virginia G. Piper Cancer Center and Side-Out Foundation team up for breast cancer study

Many women live with breast cancer that does not respond to standard medical treatment, a condition that researchers at the Virginia G. Piper Cancer Center at Scottsdale Healthcare want to change by aggressively targeting specific genes.

12 Mar 2010

Illumina sequences DNA of American actress Glenn Close

Illumina, Inc. today announced that it has sequenced the DNA of American actress Glenn Close, the first publicly named female to have her DNA sequenced to full coverage.

From Illumina, Inc. 11 Mar 2010

BIOCRATES Life Sciences, CHENOMX announce co-marketing agreement

Austrian biomarker developer BIOCRATES Life Sciences AG announced today that it entered a co-marketing agreement with Canadian-based CHENOMX Inc. Both enterprises focus on a new and highly promising technology aimed at generating a metabolic profile of the human organism that can be used to monitor the effects of disease, nutrition, toxins, environment, or drugs on an organism.

10 Mar 2010

Cellzome, GSK form second major alliance to develop new anti-inflammatory drugs

Cellzome today announced that it has formed a second strategic alliance with GlaxoSmithKline (GSK). This new collaboration gives GSK exclusive access to Cellzome's proprietary Episphere(TM) technology in the emerging field of epigenetics as applied to immunoinflammatory disease. Epigenetic mechanisms play a key role in controlling immune cell differentiation and inflammatory gene expression during an excessive inflammatory response.

10 Mar 2010

Side-Out Foundation sponsors new advanced breast cancer clinical trial

The Side-Out Foundation, which pairs volleyball enthusiasts with breast cancer researchers, is sponsoring a new clinical trial for up to 25 patients with advanced breast cancer.

10 Mar 2010

GeneGo's industry-FDA MetaTox partnership program: Tools and contents released

GeneGo announces the release of the first set of tools and content to come out of its industry-FDA MetaTox™ partnership program. The MetaTox partnership is developing a unique comprehensive systems toxicology suite designed for compound safety assessment in chemical and pharmaceutical R&D.

8 Mar 2010